We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 1.85% | 27.475 | 27.375 | 27.57 | 27.61 | 26.94 | 26.945 | 404,068 | 22:50:04 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Bayer AG on Tuesday said the U.S. Food and Drug Administration granted priority review to finerenone for patients with chronic kidney disease and type 2 diabetes.
The Leverkusen, Germany, chemical and pharmaceutical company said finerenone offers a potential new strategy to delay the progression of chronic kidney disease in people with type 2 diabetes while reducing the risk of cardiovascular events.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.
Bayer said there is currently a significant unmet medical need for the nearly 40% of people in the U.S. with type 2 diabetes who will develop chronic kidney disease, a progressive condition can lead to kidney damage and eventual failure.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 12, 2021 09:05 ET (14:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
